EUVIMEDEUVIMED entdecken
Crossref

Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older

Molly O Meeker iD, Ryan Ivancic iD, Brad deSilva, Laura A Matrka iD

The Laryngoscope · 2025

DOI: 10.1002/lary.32123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Molly O Meeker und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Respiratory Tract Infections, Vaccination. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Gardasil vaccination has been effective as primary prevention and adjuvant therapy for recurrent respiratory papillomatosis (RRP). We present an update to our previous research reporting a significant increase in the intersurgical interval (ISI) after adjuvant Gardasil vaccination. Our objectives were: (1) to assess the durability of Gardasil as an adjuvant in RRP with longer‐term follow‐up and an expanded cohort, and (2) to better control for the use of other non‐Gardasil adjuvant therapies.

Methods

A retrospective chart review of adult patients > 45 years diagnosed with RRP from 2008 to 2022 was conducted. Patients were considered vaccinated if they received at least two Gardasil doses.

Results

There were 51 total patients, 14 vaccinated and 37 unvaccinated. There was a significant increase in the ISI for the vaccinated group from 126 to 304 days ( p = 0.0039), with 100.1 ± 47.3 months follow‐up. Our previous study, performed at 49.7 ± 30.3 months follow‐up, found an ISI of 494 days in the vaccinated group. Non‐Gardasil adjuvant use was greater in the vaccinated group, but we found no significant effect of non‐Gardasil adjuvant use on ISI in the unvaccinated group ( p = 0.34).

Conclusions

Adjuvant Gardasil use in RRP patients > 45 years significantly increases the ISI, which supports findings from our previous study. However, the magnitude of this effect may wane with time, with the ISI remaining significant but downtrending from 494 to 304 days. This data raise the question of whether booster Gardasil dosing warrants investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Respiratory Tract InfectionsVaccinationHumansRetrospective StudiesFemaleMiddle AgedMaleAgedFollow-Up Studies

Stichwörter der Autor:innen

benign lesionslaryngologypapillomatosis/recurrent respiratory papillomatosis

Substanzen

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Autor:innen und Institutionen

  • College of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

ORCID-Profile: Molly O Meeker, Ryan Ivancic, Laura A Matrka

Zitieren

APA

Meeker, M. O., Ivancic, R., deSilva, B., & Matrka, L. A. (2025). Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older. The Laryngoscope. https://doi.org/10.1002/lary.32123

Vancouver

Meeker MO, Ivancic R, deSilva B, Matrka LA. Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older. The Laryngoscope. 2025. doi:10.1002/lary.32123

BibTeX
@article{Meeker2025,
  author = {Meeker, Molly O and Ivancic, Ryan and deSilva, Brad and Matrka, Laura A},
  title = {Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older},
  journal = {The Laryngoscope},
  year = {2025},
  doi = {10.1002/lary.32123}
}
Kostenlos starten →